FDA Lifts Clinical Hold On Dynavax's Hep B Vaccine Heplisav, Narrows Population
This article was originally published in The Pink Sheet Daily
Executive Summary
The firm is hoping to gain licensure for chronic kidney disease patients first, and eventually to expand the indication to the broader hepatitis B vaccination population.